Is DGX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Quest Diagnostics (DGX) rests on Organic volume growth: Requisition volumes grew roughly 11 percent year over year in Q1 2026, with organic volume up about 10.8 percent. Revenue (TTM) is ~$11.5B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Whether DGX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Quest Diagnostics operates one of the largest clinical laboratory networks in the United States, processing billions of test results a year across a footprint of patient service centers, hospital and physician outreach relationships, and consumer-initiated testing. Its core Diagnostic Information Services segment spans routine testing (blood counts, cholesterol, metabolic panels) plus a growing base of advanced molecular and genomic diagnostics in oncology, neurology, women's health, and infectious disease. Scale, a national logistics network, and long-standing payer contracts are the company's main moats in a fragmented roughly $100 billion US lab market where Quest and Labcorp together hold the top tier. The investment picture is that of a defensive healthcare-services business trading at a moderate valuation, with growth coming from organic volume, a steady cadence of tuck-in lab acquisitions, and a mix shift toward higher-value advanced testing. Q1 2026 showed revenue up about 9 percent and adjusted EPS up double digits, prompting raised full-year guidance. The offsetting concern is reimbursement policy: Medicare rate schedules under PAMA and broader payer pressure cap pricing power, so the bull case rests on volume, efficiency (including AI and automation), and acquisitions rather than price increases.
What's the case for buying DGX?
1. Organic volume growth
Requisition volumes grew roughly 11 percent year over year in Q1 2026, with organic volume up about 10.8 percent. Quest is winning share in physician office, hospital outreach, and health-system reference work, and consumer-initiated testing adds an incremental channel. Volume, not price, is the primary top-line lever.
2. Acquisitions as a growth engine
M&A remains central to the strategy, with a steady stream of tuck-in lab and hospital-outreach deals. The Spectra Laboratories asset purchase from Fresenius (roughly $34 million) is expected to add about $100 million of revenue in 2026. These deals fold volume into Quest's existing network at improving margins.
3. Advanced diagnostics mix shift
Quest is pushing beyond routine testing into higher-value molecular and genomic diagnostics across oncology, neurology, and women's health, including new tests such as a myeloma assay. This mix shift supports revenue per requisition and differentiates Quest from purely commoditized lab work.
4. Productivity from AI and automation
Management credits AI and lab automation for margin gains and higher throughput. Adjusted operating margin held in the mid-teens in Q1 2026, and continued efficiency is a key reason guidance was raised even as reimbursement stays flat to down.
What are the risks to DGX?
The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin.
How is DGX valued? (as of July 2026)
Snapshot for DGX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$11.5B
- 2026 revenue guidance: ~$11.78B to $11.9B
- 2026 adj. EPS guidance: ~$10.63 to $10.83
- Market cap: ~$22.8B
- P/E (trailing / forward): ~22.8x / ~19.2x
- Dividend (annual / yield): ~$3.44 / ~1.6%
In Q1 2026 Quest reported revenue of about $2.9 billion (up 9.2 percent) and adjusted EPS of $2.50 (up 13.1 percent), and raised full-year guidance. The stock traded near $205 in mid-July 2026 at a forward P/E under 20, a moderate multiple below primary competitor Labcorp. The dividend has risen for 15 consecutive years, most recently a 7.5 percent increase.
How do you decide if DGX is a buy?
Rather than asking whether DGX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold DGX indirectly through an index or sector ETF before adding more.
For the full picture, see the DGX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about DGX against your real portfolio and see your actual exposure before deciding.
The bottom line on DGX
The bottom line: Quest Diagnostics's story right now is Organic volume growth, with revenue (ttm) at ~$11.5B. If you believe that narrative continues, the call is about sizing DGX sensibly and checking overlap with what you own; if you doubt it (the risk: the largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around DGX with Walnut
Use Quest Diagnostics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is DGX a good stock to buy right now?
+
The case for Quest Diagnostics right now is Organic volume growth, with revenue (ttm) at ~$11.5B. If you believe that thesis holds, DGX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Quest Diagnostics do?
+
Quest Diagnostics operates one of the largest clinical laboratory networks in the United States, processing billions of test results a year across a footprint of patient service ce
What are the main risks of DGX?
+
The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin.
What does Quest Diagnostics do?
+
Quest Diagnostics is one of the largest US clinical laboratory operators. It performs diagnostic testing (from routine blood and metabolic panels to advanced molecular and genomic tests) for physicians, hospitals, employers, health plans, and consumers across a national network of labs and patient service centers.
Is DGX a large company?
+
Yes. As of July 2026 Quest Diagnostics has a market capitalization around $22.8 billion and trailing-twelve-month revenue near $11.5 billion, making it a large-cap company and one of the two leaders in the US independent lab market alongside Labcorp.
How fast is Quest growing?
+
In Q1 2026 revenue rose about 9.2 percent year over year with requisition volume up roughly 11 percent. Full-year 2026 guidance implies revenue growth of about 6.8 to 7.8 percent, driven by organic volume, acquisitions, and advanced diagnostics rather than price increases.
Does DGX pay a dividend?
+
Yes. Quest pays an annual dividend of about $3.44 per share for a yield near 1.6 percent as of July 2026. It has raised the dividend for 15 consecutive years, most recently a 7.5 percent increase, which appeals to income-oriented investors.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell DGX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.